Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study

• DOI: 10.1371/journal.pone.0221317
• Publication Date: 2019-08-29T17:36:41Z
• Authors: Carmelo Magri; Michael Schramme; Marine Febre; Eddy Cauvin; Fabrice Labadie; Nathalie Saulnier; Isé François; Antoine Lechartier; David Aebischer; Anne-Sophie Moncelet; Stéphane Maddens
• Keywords: Metacarpophalangeal joint

The purpose of this prospective study was to evaluate the effects single and repeated intra-articular administration allogeneic, umbilical cord-derived, neonatal mesenchymal stem cells (MSC) in horses with lameness due osteoarthritis (OA) a metacarpophalangeal joint (MPJ). Twenty-eight were included. Horses divided into two groups. group MSC1 received an MSC injection at M0 placebo M1 (1 month after M0). MSC2 injections M1. Joint performed blinded syringe. Clinical assessment by treating veterinarian M1, M2 M6 (2 6 months M0), including evaluation, palpation flexion joint. Radiographic examination treated joints inclusion M6. Radiographs anonymized assessed 2 ECVDI LA associate members. Short term safety owner survey. A 2-month rehabilitation program recommended veterinarians. There significant improvement total clinical score for both no difference between groups any time point study. radiographic OA score, osteophyte space width subchondral bone Owner-detected adverse recorded 18% horses. Lameness caused improved significantly over 6-month duration treatment allogeneic cord-derived MSCs combined 8 weeks rest rehabilitation. is apparent benefit 1-month interval MPJ when compared effect injection.